Launch of new first-in-class products will push RSV market to $6.3 billion by 2030

4 September 2021
globaldata

The market for respiratory syncytial virus (RSV) prophylaxis is expected to skyrocket from $454.8 million in 2020 to $6.3 billion by 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan, and Australia), expanding at an impressive compound annual growth rate (CAGR) of 30.1%.

The main driver of growth will be the launch of multiple first-in-class products, according to data and analytics company GlobalData.

GlobalData’s latest report, ‘ Respiratory Syncytial Virus (RSV) Prophylaxis - Global Drug Forecast and Market Analysis to 2030’, reveals that the main driver of growth will be the launch of multiple first-in-class products to prevent medically significant RSV infections, including improved single-dose monoclonal antibodies (MAbs), along with maternal, adult, and pediatric RSV vaccines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology